123 related articles for article (PubMed ID: 21853929)
1. Evaluation of IL-10 and TGF-β levels and myeloid and lymphoid dendritic cells in ovarian cancer patients.
Wertel I; Polak G; Tarkowski R; Kotarska M
Ginekol Pol; 2011 Jun; 82(6):414-20. PubMed ID: 21853929
[TBL] [Abstract][Full Text] [Related]
2. SDF-1alpha/CXCL12 and dendritic cells in ovarian cancer microenvironment.
Wertel I; Polak G; Tarkowski R; Kotarska M
Ginekol Pol; 2011 Jun; 82(6):421-5. PubMed ID: 21853930
[TBL] [Abstract][Full Text] [Related]
3. Relationship between RANTES and dendritic cells in ovarian cancer patients.
Wertel I; Tarkowski R; Bednarek W; Kotarski J
Front Biosci (Elite Ed); 2011 Jan; 3(1):227-32. PubMed ID: 21196302
[TBL] [Abstract][Full Text] [Related]
4. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer.
Santin AD; Bellone S; Ravaggi A; Roman J; Smith CV; Pecorelli S; Cannon MJ; Parham GP
BJOG; 2001 Aug; 108(8):804-8. PubMed ID: 11510703
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer.
Wertel I; Polak G; Bednarek W; Barczyński B; Roliński J; Kotarski J
Cytometry B Clin Cytom; 2008 Jul; 74(4):251-8. PubMed ID: 18302193
[TBL] [Abstract][Full Text] [Related]
6. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines.
Zhou J; Ye F; Chen H; Lv W; Gan N
J Int Med Res; 2007; 35(3):290-300. PubMed ID: 17593856
[TBL] [Abstract][Full Text] [Related]
7. Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients.
Wertel I; Surówka J; Polak G; Barczyński B; Bednarek W; Jakubowicz-Gil J; Bojarska-Junak A; Kotarski J
Tumour Biol; 2015 Jun; 36(6):4811-7. PubMed ID: 25647263
[TBL] [Abstract][Full Text] [Related]
8. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
9. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-7 and suppression of local peritoneal immunity in ovarian carcinoma.
Xie X; Ye D; Chen H; Lu W; Cheng B; Zhong H
Int J Gynaecol Obstet; 2004 May; 85(2):151-8. PubMed ID: 15099777
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kulesza-Bronczyk B; Kinalski M; Terlikowski SJ
Eur Cytokine Netw; 2013; 24(3):106-13. PubMed ID: 24197277
[TBL] [Abstract][Full Text] [Related]
12. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
[TBL] [Abstract][Full Text] [Related]
13. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
Moradi MM; Carson LF; Weinberg B; Haney AF; Twiggs LB; Ramakrishnan S
Cancer; 1993 Oct; 72(8):2433-40. PubMed ID: 8402460
[TBL] [Abstract][Full Text] [Related]
14. Myeloid and lymphoid dendritic cells in the peritoneal fluid of women with ovarian cancer.
Wertel F; Polak G; Roliński J; Barczyński B; Kotarski J
Adv Med Sci; 2006; 51():174-7. PubMed ID: 17357302
[TBL] [Abstract][Full Text] [Related]
15. Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer.
Okła K; Czerwonka A; Wawruszak A; Bobiński M; Bilska M; Tarkowski R; Bednarek W; Wertel I; Kotarski J
Front Immunol; 2019; 10():691. PubMed ID: 31001284
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
17. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients.
Dalal V; Kumar R; Kumar S; Sharma A; Kumar L; Sharma JB; Roy KK; Singh N; Vanamail P
Clin Chim Acta; 2018 Jul; 482():27-32. PubMed ID: 29572186
[TBL] [Abstract][Full Text] [Related]
18. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer.
Cândido EB; Silva LM; Carvalho AT; Lamaita RM; Filho RM; Cota BD; da Silva-Filho AL
Reprod Sci; 2013 Jul; 20(7):828-37. PubMed ID: 23239818
[TBL] [Abstract][Full Text] [Related]
19. Elevated Th22 cells and related cytokines in patients with epithelial ovarian cancer.
Wang T; Zhang Z; Xing H; Wang L; Zhang G; Yu N; Wang J; Guo W; Jiang J
Medicine (Baltimore); 2017 Oct; 96(43):e8359. PubMed ID: 29069020
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of myeloid and lymphoid dendritic cells in peritoneal fluid in women with non-malignant ovarian tumors.
Wertel I; Kotarski J; Roliński J; Bojarska-Junak A; Gogacz M
Am J Reprod Immunol; 2003 Sep; 50(3):238-42. PubMed ID: 14629029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
